<DOC>
	<DOCNO>NCT02894580</DOCNO>
	<brief_summary>The efficacy implantable cardioverter-defibrillators ( ICD ) primary prevention sudden cardiac death ( SCD ) well demonstrate pivotal study publish 10 year ago implantation 's condition tend change .</brief_summary>
	<brief_title>Primary Prevention Sudden Cardiac Death ( PREV-DEATH )</brief_title>
	<detailed_description>The clinical efficacy implantable cardioverter defibrillator ( ICD ) method primary prevention sudden cardiac death ( SCD ) well demonstrate today . Unfortunately , selection criterion patient deem risk lack specificity . For asymptomatic patient leave ventricular dysfunction ( LVEF ) , current guideline support implantation ICD LVEF ≤35 % . This target population correspond one study Sudden Cardiac Death HEart Failure Trial ( SCD-HeFT ) . This trial 10 year old . The proportion patient LVEF &gt; 30 % low ( 17 % ) analysis subgroup show decrease mortality ( hazard ratio = 1.08 [ 0.57-2.07 ] ) . That usefulness ICD segment population remain subject controversy . Moreover , SCD-HeFT offer resynchronization therapy despite fact 40 % patient include QRS signal duration ≥120ms . Conditions implantation since change considerably . The `` routine '' nature implantation procedure desire maximize patient 's protection lead u address implantation easily . As resynchronization , must attempt patient severe heart failure , LVEF ≤35 % QRS sufficiently prolong . This suggest implanted population different nowadays pivotal study term mean LVEF implant material . However , two factor significantly correlate risk SCD ... Therefore , analysis do sample patient receive ICD primary prevention set . This study focus effect resynchronization LVEF implantation subsequent outcome . The result broadly compare SCD-HeFT .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<criteria>primoimplantation primary prevention New York Heart Association ( NYHA ) II III chronic heart failure due ischemic non ischemic cause LVEF ≤35 % Cardiomyopathy dilate cardiomyopathy hypertrophic cardiomyopathy , congenital valvular heart disease Patients NYHA class I IV heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>